---
schema_version: "secwatch.filing_event.v1"
accession: "0001690585-26-000033"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2026-08-04T20:05:21+00:00"
generated_at: "2026-08-04T20:07:10.060057+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Dianthus Q2 net loss $50.2M; CIDP trial 75% response; cash $1.2B

## Summary
- Net loss $50.2M ($0.90/share) vs $31.6M ($0.88) in Q2 2025; R&D $48.7M, G&A $13.6M.
- Cash $1.2B as of June 30, 2026, providing runway into 2030.
- Phase 3 CAPTIVATE (CIDP) interim: 75% response rate in first 40 patients; Part B guidance by YE'26.
- Phase 3 EMERGE (gMG) initiated; top-line results expected 2H'28.
- Phase 2 MoMeNtum (MMN) enrollment completed (46 patients); top-line Dec '26.

## SEC filing metadata
- accession: 0001690585-26-000033
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2026-08-04T20:05:21+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000169058526000033/0001690585-26-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000169058526000033/dnth-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001690585-26-000033
- JSON: https://secwatch.observer/filing/0001690585-26-000033.json
- Plain text: https://secwatch.observer/filing/0001690585-26-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.